ASH11 Pressconference  Assessing Therapeutic Strategies and Improving Quality of Life
Channel: 0ncoletter
Date: 2012-10-11

ASH11 Pressconference  Assessing Therapeutic Strategies and Improving Quality of Life for Patients with Sickle Cell Disease:

Hydroxyurea Treatment of Young Children with Sickle Cell Anemia: Safety and Efficacy of Continued Treatment -- the BABY HUG Follow-up Study

Genotoxicity Associated with Hydroxyurea Exposure in Infants with Sickle Cell Anemia: Results From the BABY-HUG Phase III Clinical Trial

Pre-Operative Transfusion Reduces Serious Adverse Events in Patients with Sickle Cell Disease (SCD): Results From the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) Randomised Controlled Multicentre Clinical Trial